AR129388A1 - Compuestos aza-tetracíclicos de oxazepina y usos de los mismos - Google Patents

Compuestos aza-tetracíclicos de oxazepina y usos de los mismos

Info

Publication number
AR129388A1
AR129388A1 ARP230101266A ARP230101266A AR129388A1 AR 129388 A1 AR129388 A1 AR 129388A1 AR P230101266 A ARP230101266 A AR P230101266A AR P230101266 A ARP230101266 A AR P230101266A AR 129388 A1 AR129388 A1 AR 129388A1
Authority
AR
Argentina
Prior art keywords
unsubstituted
substituted
alkyl
cancer
halogen
Prior art date
Application number
ARP230101266A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Leo Landry
Christian Nilewski
Michael Siu
Elisia Villemure
Yong Wang
Binqing Wei
Melissa Ann Ashley
Steven Do
Lewis John Gazzard
Samantha Alyson Green
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR129388A1 publication Critical patent/AR129388A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP230101266A 2022-05-19 2023-05-19 Compuestos aza-tetracíclicos de oxazepina y usos de los mismos AR129388A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263343959P 2022-05-19 2022-05-19

Publications (1)

Publication Number Publication Date
AR129388A1 true AR129388A1 (es) 2024-08-21

Family

ID=86895902

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101266A AR129388A1 (es) 2022-05-19 2023-05-19 Compuestos aza-tetracíclicos de oxazepina y usos de los mismos

Country Status (17)

Country Link
US (3) US20240025919A1 (cg-RX-API-DMAC7.html)
EP (1) EP4526309A1 (cg-RX-API-DMAC7.html)
JP (2) JP7735594B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250013185A (cg-RX-API-DMAC7.html)
CN (1) CN119365467A (cg-RX-API-DMAC7.html)
AR (1) AR129388A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023272945A1 (cg-RX-API-DMAC7.html)
CA (1) CA3257445A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003491A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024017330A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240508A (cg-RX-API-DMAC7.html)
IL (1) IL316696A (cg-RX-API-DMAC7.html)
MX (1) MX2024014176A (cg-RX-API-DMAC7.html)
PE (1) PE20250752A1 (cg-RX-API-DMAC7.html)
TW (1) TW202400170A (cg-RX-API-DMAC7.html)
WO (1) WO2023225302A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202408076B (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
MX2023015533A (es) * 2021-06-21 2024-01-23 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
CN115557974A (zh) * 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CN119365467A (zh) 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
TW202409051A (zh) * 2022-07-27 2024-03-01 大陸商江蘇恆瑞醫藥股份有限公司 稠環類化合物、其製備方法及其在醫藥上的應用
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
EP4716531A2 (en) * 2023-05-22 2026-04-01 Board of Regents, The University of Texas System Heterocyclic compounds as nras inhibitors
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
WO2025045141A1 (en) * 2023-08-31 2025-03-06 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202540122A (zh) * 2023-11-22 2025-10-16 美商建南德克公司 Kras-g12d之氮雜-四環氧氮呯抑制劑的多晶型物及合成方法
WO2025123007A1 (en) * 2023-12-08 2025-06-12 Kestrel Therapeutics Inc. Ras inhibitors and methods of use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025194134A1 (en) 2024-03-15 2025-09-18 Genentech, Inc. Linearly substituted oxazepin-5-one kras-g12d inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026011344A1 (en) * 2024-07-10 2026-01-15 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026039659A1 (en) * 2024-08-14 2026-02-19 Board Of Regents, The University Of Texas System Heterocyclic compounds as ras inhibitors
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026073024A1 (en) * 2024-09-30 2026-04-02 Gilead Sciences, Inc. Kras g12d inhibitors for the treatment of cancer
WO2026080548A1 (en) 2024-10-10 2026-04-16 Genentech, Inc. Method of treating cancer using the kras g12d inhibitor gcd-7035
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors
CN121108144B (zh) * 2025-09-02 2026-07-03 领泰生物医药(绍兴)有限公司 一种含氮杂多环化合物的制备方法及其中间体

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2020097537A2 (en) 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
CN114615981B (zh) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
CN116867792A (zh) 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CN117043167A (zh) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
MX2023015533A (es) * 2021-06-21 2024-01-23 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
CN115557974A (zh) 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
CN117677624A (zh) * 2021-07-19 2024-03-08 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
CA3226720A1 (en) * 2021-07-23 2023-01-26 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
WO2023018812A1 (en) 2021-08-10 2023-02-16 Amgen Inc. Heterocyclic compounds and methods of use
JP2024532735A (ja) 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
TW202315626A (zh) 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
WO2023030495A1 (en) 2021-09-03 2023-03-09 Ascentage Pharma (Suzhou) Co., Ltd. Kras inhibitors
CN118019746A (zh) 2021-09-27 2024-05-10 北京加科思新药研发有限公司 多环稠环衍生物及其用途
CN116199703A (zh) 2021-12-01 2023-06-02 江苏恒瑞医药股份有限公司 稠合四环杂环化合物、其制备方法及其在医药上的应用
WO2023103906A1 (zh) 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CN116332948A (zh) 2021-12-22 2023-06-27 翰森生物有限责任公司 一种含氮四环化合物及其制备方法和药用用途
JP2025504041A (ja) 2022-01-30 2025-02-06 シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド キノリン系化合物及びその使用
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2023265688A1 (en) 2022-05-06 2024-10-17 PAQ Therapeutics Inc. Kras g12d proteolysis targeting chimeras
CN119365467A (zh) 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
TW202409051A (zh) 2022-07-27 2024-03-01 大陸商江蘇恆瑞醫藥股份有限公司 稠環類化合物、其製備方法及其在醫藥上的應用
CN117462688A (zh) 2022-07-28 2024-01-30 江苏恒瑞医药股份有限公司 一种包含kras g12d抑制剂的组合物
KR20250037564A (ko) 2022-07-29 2025-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Kras g12d 억제제를 포함하는 약학적 조성물
WO2024032704A1 (en) 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024041573A1 (en) 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
CN117771378A (zh) 2022-09-29 2024-03-29 贝达药业股份有限公司 提高kras抑制剂生物利用度的药物组合及其应用
EP4595963A4 (en) * 2022-09-30 2026-01-21 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE TO INDUCE IMMUNOGENEOUS CELL DEATH AND USE
TW202430182A (zh) * 2022-12-14 2024-08-01 大陸商上海科州藥物研發有限公司 作為kras抑制劑的雜環化合物,及其製備和治療用途
CN118221699A (zh) 2022-12-20 2024-06-21 江苏恒瑞医药股份有限公司 一种kras g12d抑制剂的可药用盐、晶型及其制备方法
TW202430184A (zh) 2022-12-20 2024-08-01 大陸商江蘇恒瑞醫藥股份有限公司 Kras g12d抑制劑的結晶形式及製備方法

Also Published As

Publication number Publication date
CA3257445A1 (en) 2023-11-23
ZA202408076B (en) 2026-01-28
WO2023225302A1 (en) 2023-11-23
US20240025919A1 (en) 2024-01-25
CN119365467A (zh) 2025-01-24
JP2026000916A (ja) 2026-01-06
KR20250013185A (ko) 2025-01-31
PE20250752A1 (es) 2025-03-13
US20260062425A1 (en) 2026-03-05
US20240368186A1 (en) 2024-11-07
CL2024003491A1 (es) 2025-04-11
JP7735594B2 (ja) 2025-09-08
MX2024014176A (es) 2024-12-06
TW202400170A (zh) 2024-01-01
US12338256B2 (en) 2025-06-24
CO2024017330A2 (es) 2024-12-30
AU2023272945A1 (en) 2024-11-07
CR20240508A (es) 2024-12-20
EP4526309A1 (en) 2025-03-26
IL316696A (en) 2024-12-01
JP2025517395A (ja) 2025-06-05

Similar Documents

Publication Publication Date Title
AR123848A1 (es) Compuestos espiro heterocíclicos y métodos de uso
PE20230238A1 (es) Inhibidores de kras g12c
PE20250752A1 (es) Compuestos aza-tetraciclicos de oxazepina y usos de los mismos
AR111281A1 (es) Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
AU2012328979B2 (en) Method of treating gastrointestinal stromal tumors
MX2025013001A (es) Inhibidores espiro-heterocíclicos de las proteínas mutantes kras g12c y usos de los mismos.
MX2025004109A (es) Inhibidores heterocíclicos de las proteínas mutantes kras g12c y utilizaciones de los mismos
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR125425A1 (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
AR126108A1 (es) Tratamientos para la degradación del braf mutante
JP2017524668A (ja) ヒストンメチルトランスフェラーゼ及びdnaメチルトランスフェラーゼの二重阻害剤としての新規化合物
RU2012127792A (ru) Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы
AR119244A1 (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
He et al. Discovery of a highly potent and orally bioavailable STAT3 dual phosphorylation inhibitor for pancreatic cancer treatment
AR119234A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
AR045931A1 (es) Derivados de piperazina
ES2376277T3 (es) Uso del �?cido cafeico y dervados como agentes anticancerosos.
ES2907837T3 (es) 1,2,3-triazoles 1,5-disustituidos son inhibidores de las GTPasas Rac/Cdc42
JP7114745B2 (ja) トリプルネガティブ乳癌および卵巣癌の治療のための化合物
JP2013511526A5 (cg-RX-API-DMAC7.html)
KR20250020713A (ko) 벤젠술폰아미드 유도체 및 지질 래프트 조정 방법
JP2021523109A (ja) 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホリジン
US20190127325A1 (en) Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents
WO2023194310A1 (en) Therapeutic combination of kras g12c inhibitor and tead inhibitor
Abedinpour et al. The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo